IL271606B2 - Gastro-resistant controlled release oral dosage forms - Google Patents

Gastro-resistant controlled release oral dosage forms

Info

Publication number
IL271606B2
IL271606B2 IL271606A IL27160619A IL271606B2 IL 271606 B2 IL271606 B2 IL 271606B2 IL 271606 A IL271606 A IL 271606A IL 27160619 A IL27160619 A IL 27160619A IL 271606 B2 IL271606 B2 IL 271606B2
Authority
IL
Israel
Prior art keywords
compound
dosage form
subject
gastro
resistant
Prior art date
Application number
IL271606A
Other languages
English (en)
Hebrew (he)
Other versions
IL271606B1 (en
IL271606A (en
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62904624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL271606(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of IL271606A publication Critical patent/IL271606A/en
Publication of IL271606B1 publication Critical patent/IL271606B1/en
Publication of IL271606B2 publication Critical patent/IL271606B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL271606A 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms IL271606B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523204P 2017-06-21 2017-06-21
PCT/US2018/038853 WO2018237207A1 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms

Publications (3)

Publication Number Publication Date
IL271606A IL271606A (en) 2020-02-27
IL271606B1 IL271606B1 (en) 2024-01-01
IL271606B2 true IL271606B2 (en) 2024-05-01

Family

ID=62904624

Family Applications (3)

Application Number Title Priority Date Filing Date
IL319156A IL319156A (en) 2017-06-21 2018-06-21 Controlled-release oral dosage forms are resistant to gastric acid.
IL271606A IL271606B2 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms
IL308650A IL308650B2 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL319156A IL319156A (en) 2017-06-21 2018-06-21 Controlled-release oral dosage forms are resistant to gastric acid.

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL308650A IL308650B2 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms

Country Status (15)

Country Link
US (3) US11464744B2 (enExample)
EP (1) EP3641732A1 (enExample)
JP (3) JP2020525436A (enExample)
CN (1) CN111511353A (enExample)
AU (2) AU2018290287B2 (enExample)
BR (1) BR112019027398A2 (enExample)
CA (1) CA3067031A1 (enExample)
CL (1) CL2019003743A1 (enExample)
CO (1) CO2019014496A2 (enExample)
IL (3) IL319156A (enExample)
MX (1) MX2023002994A (enExample)
PE (1) PE20200732A1 (enExample)
UA (1) UA127349C2 (enExample)
WO (1) WO2018237207A1 (enExample)
ZA (1) ZA202409847B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2968977A1 (en) 2014-12-02 2016-06-09 Minerva Neurosciences, Inc. Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
EP3641732A1 (en) 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
WO2020041504A1 (en) 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
IT201800011125A1 (it) * 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico
CA3243767A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. USE OF ROLUPERIDONE IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160152597A1 (en) * 2014-12-02 2016-06-02 Minerva Neurosciences, Inc. Compositions and methods for treating schizophrenia

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325063B1 (en) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
ZA908641B (en) 1989-10-27 1992-06-24 Du Pont (n-phthalimidoalkyl)piperidines
NZ251610A (en) 1992-04-23 1996-02-27 Merrell Dow Pharma 4-imidomethyl-1-(2-phenyl-2-oxoethyl)piperidine derivatives and pharmaceutical compositions
PT1260512E (pt) 2000-02-29 2007-10-10 Mitsubishi Pharma Corp ''novos derivados de amida cíclicos''
WO2002026214A1 (en) 2000-09-29 2002-04-04 Solvay Pharmaceuticals B.V. Ion-strength independent sustained release pharmaceutical formulation
US20050095292A1 (en) 2003-10-29 2005-05-05 Wyeth Sustained release pharmaceutical compositions
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
DOP2006000125A (es) 2005-06-06 2006-12-31 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia
JP2009525979A (ja) 2006-02-07 2009-07-16 田辺三菱製薬株式会社 ４−アシルアミノピリジン誘導体を介した神経新生
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
JP2008273954A (ja) 2007-03-30 2008-11-13 Mitsubishi Tanabe Pharma Corp うつ病の予防及び／又は治療剤
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP2246331A1 (en) 2009-04-24 2010-11-03 Westfälische Wilhelms-Universität Münster NR2B-selective NMDA-receptor antagonists
JP5640079B2 (ja) * 2009-05-18 2014-12-10 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 油滴含有組成物
UY33455A (es) 2010-06-16 2012-01-31 Teijin Pharma Ltd Tableta con núcleo recubierto de liberación controlada
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
EP3335731B1 (en) 2010-07-20 2024-09-04 Minerva Neurosciences, Inc. Use of cyclic amide derivatives to treat sleep disorders
EP4070794A3 (en) 2010-07-20 2023-01-18 Minerva Neurosciences, Inc. Methods of use cyclic amide derivatives to treat sigma receptor-mediated disorders
US20120040008A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP2685966A1 (en) 2011-03-17 2014-01-22 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
CA2845228C (en) * 2011-08-16 2021-08-10 Baker Idi Heart & Diabetes Institute Holdings Limited Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds
BR112015023124A2 (pt) * 2013-03-14 2017-07-18 Therabiome Llc liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal
CN104586771B (zh) * 2013-10-30 2018-01-16 广州朗圣药业有限公司 一种盐酸坦洛新缓释微丸制剂
MX2016014192A (es) 2014-04-30 2017-05-01 Incyte Corp Procesos para preparar un inhibidor de cinasas de janus 1 (jak1) y nuevas formas de este.
EP3144308B1 (en) 2014-05-16 2020-06-24 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
RU2697851C2 (ru) * 2014-08-13 2019-08-21 Седарс-Синаи Медикал Сентер Антиметаногенные композиции и их применение
WO2017066134A1 (en) * 2015-10-16 2017-04-20 Merck Sharp & Dohme Corp. Processes for preparing formulations for gastrointestinal-targeted therapies
SG11201810358YA (en) 2016-05-25 2018-12-28 Mitsubishi Tanabe Pharma Corp Compositions and methods for treating negative symptoms in non-schizophrenic patients
EP3641732A1 (en) 2017-06-21 2020-04-29 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
WO2020041504A1 (en) 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
US12441701B2 (en) 2019-06-28 2025-10-14 Tapi Czech Industries S.R.O. Solid state forms of roluperidone and salts thereof
CA3243767A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. USE OF ROLUPERIDONE IN THE PREVENTION OF RELAPSE IN PATIENTS WITH SCHIZOPHRENIA

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160152597A1 (en) * 2014-12-02 2016-06-02 Minerva Neurosciences, Inc. Compositions and methods for treating schizophrenia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUSSAN SINGH DEEP ET AL.:, A REVIEW ON RECENT ADVANCES OF ENTERIC COATING, 1 November 2012 (2012-11-01) *
KAMEL SAMIR ET AL.:, PHARMACEUTICAL SIGNIFICANCE OF CELLULOSE: A REVIEW, 1 January 2008 (2008-01-01) *

Also Published As

Publication number Publication date
JP2025134828A (ja) 2025-09-17
IL271606B1 (en) 2024-01-01
WO2018237207A1 (en) 2018-12-27
UA127349C2 (uk) 2023-07-26
CL2019003743A1 (es) 2020-07-03
AU2018290287A1 (en) 2020-01-16
CO2019014496A2 (es) 2020-04-01
JP2023175778A (ja) 2023-12-12
IL319156A (en) 2025-04-01
EP3641732A1 (en) 2020-04-29
IL308650B1 (en) 2025-04-01
US12048768B2 (en) 2024-07-30
RU2020102015A (ru) 2021-07-21
US20250009665A1 (en) 2025-01-09
BR112019027398A2 (pt) 2020-07-07
AU2018290287B2 (en) 2024-06-13
CN111511353A (zh) 2020-08-07
US11464744B2 (en) 2022-10-11
US20220401368A1 (en) 2022-12-22
MX2023002994A (es) 2023-09-15
RU2020102015A3 (enExample) 2021-10-04
AU2024219717A1 (en) 2024-10-03
IL308650A (en) 2024-01-01
ZA202409847B (en) 2025-09-25
IL308650B2 (en) 2025-08-01
CA3067031A1 (en) 2018-12-27
PE20200732A1 (es) 2020-07-23
JP2020525436A (ja) 2020-08-27
IL271606A (en) 2020-02-27
US20190038561A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
US12048768B2 (en) Gastro-resistant controlled release oral dosage forms
US20160256398A1 (en) Compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
US20150157575A1 (en) Pharmaceutical Formulations Comprising Vilazodone
US20240277698A1 (en) Methods of using aldosterone synthase inhibitors
EP0910375B1 (en) A composition of enalapril and losartan
Sakr et al. Pharmacokinetics of buspirone extended‐release tablets: a single‐dose study
Schussheim et al. Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension
RU2812901C2 (ru) Кишечнорастворимые лекарственные формы для перорального применения с контролируемым высвобождением
US20070053975A1 (en) Ramipril formulation
CN116234555A (zh) 改良形式的曲美他嗪的改良释放制剂
TWI841545B (zh) 耐胃性控制釋放經口劑型
KR102817359B1 (ko) 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 경구용 약학 제제
CN110755397A (zh) 一种复方降压药物片剂及其用途
Agent PrACH-Pioglitazone
CA3268864A1 (en) ONCE DAILY ALDOSTERONE SYNTHASE INHIBITOR (R)-(+)-5-(P-CYANOPHENYL)-5,6,7,8-TETRAHYDROIMIDAZO[L,5-AjPYRIDINE
CN120018847A (zh) 每天一次的醛固酮合酶抑制剂(r)-(+)-5-(对氰基苯基)-5,6,7,8-四氢咪唑并[l,5-a]吡啶
CN120435291A (zh) 用于多发性硬化的治疗性酪氨酸激酶抑制剂
Hydrochloride et al. PrMYLAN-PIOGLITAZONE
Agent PrJamp-Pioglitazone
Agent PrPIOGLITAZONE HCL
NO20023463L (no) Anvendelse av rofleponid i behandling av irritabelt tarmsyndrom (IBS)
AU2017232054A1 (en) Method and composition for treating a serotonin receptor-mediated condition